INVESTIGATIONAL AGENTS FOR ISCHAEMIC CARDIOMYOPATHY TREATMENT: PRECLINICAL AND EARLY PHASE INSIGHTS [0.03%]
缺血性心肌病治疗的 investigational agents：临床前和早期阶段的见解
Paolo Ossola,Claudio Mario Ciampi,Francesco Politi et al.
Paolo Ossola et al.
Introduction: Ischemic heart disease (IHD) constitutes the most prevalent form of cardiac disease in the general population. Although current therapeutic interventions have significantly improved both quality of life and ...
Acute chest syndrome (ACS) in sickle cell disease (SCD): pathogenesis and pharmacotherapies in early clinical development [0.03%]
镰状细胞病急性胸部综合症（ACS）的发病机理及早期临床研发药物疗法
Subarna Chakravorty,Anne Greenough
Subarna Chakravorty
Introduction Sickle cell disease (SCD) is a monogenic disorder caused by a point mutation in the HBB gene, leading to the production of sickle hemoglobin (HbS). Under hypoxic or acidic conditions, HbS polymerizes within erythrocytes, leadin...
Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years? [0.03%]
过去五年中，胰腺神经内分泌肿瘤研究性药物的临床进展如何？
Paola Marino,Antonella Argentiero,Davide Quaresmini et al.
Paola Marino et al.
Introduction: Pancreatic neuroendocrine tumors (pNETs), a group of endocrine tumors that arise in the pancreas from the hormonal cells of the islets of Langerhans, are among the most common gastroenteropancreatic neuroend...
Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials [0.03%]
碳青霉烯耐药的鲍曼不动杆菌一期、二期和三期临床试验中的抗生素和非传统抗菌剂
Dimitrios S Kontogiannis,Laura T Romanos,Iva D Tzvetanova et al.
Dimitrios S Kontogiannis et al.
Introduction: Carbapenem-resistant Acinetobacter baumannii (CRAB) infections have become common in healthcare settings worldwide, yet current therapeutic options are limited. A pipeline of new antibiotics and non-traditio...
Nonamyloid-beta active immunization for the treatment of Alzheimer's disease [0.03%]
非β淀粉样蛋白活性免疫治疗阿尔茨海默病
Olivia Triplett,Nicole Varda,Boris Decourt et al.
Olivia Triplett et al.
Introduction: Alzheimer's disease (AD) is characterized by the formation of senile plaques composed of amyloid-beta (Aβ) peptides and the intraneuronal accumulation of neurofibrillary tangles composed of abnormal, hyperp...
Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives [0.03%]
针对代谢紊乱相关肝炎的 Tirzepatide：II 期临床试验结果及展望
Stefano Fiorucci,Ginevra Urbani
Stefano Fiorucci
Introduction: Tirzepatide is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. GIP and GLP-1 are incretins promoting insulin re...
Promising experimental drugs for obsessive-compulsive personality disorder [0.03%]
有前景的治疗强迫性人格障碍实验药物
Donatella Marazziti,Riccardo Gurrieri,Matteo Gambini et al.
Donatella Marazziti et al.
Introduction: Obsessive-compulsive personality disorder (OCPD) is a common psychopathological condition that generally causes a significant maladjustment in affected individuals. Despite its prevalence, there are no univo...
Investigational DNA topoisomerase I inhibitors for colorectal cancer: preclinical and early phase developments [0.03%]
用于结直肠癌的实验性DNA拓扑异构酶I抑制剂：药物的前临床和早期研究进展
Endika Martin-Encinas,Maria Fuertes,Carme Masdeu et al.
Endika Martin-Encinas et al.
Introduction: Colorectal cancer, a significant global challenge, requires innovative treatment strategies. DNA topoisomerase I inhibitors, which disrupt DNA replication in rapidly proliferating cancer cells, have shown gr...
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions [0.03%]
伊沙妥昔单抗治疗多发性骨髓瘤：临床进展及未来方向
Paul G Richardson,Elisabeth K O&#x;Donnell,Peter O&#x;Gorman et al.
Paul G Richardson et al.
Introduction: The addition of the anti-CD38 monoclonal antibody isatuximab to standard therapies is transforming the care of patients with newly diagnosed multiple myeloma (NDMM), as previously seen in the relapsed/refrac...
Investigational new drugs to treat brain metastasis from non-small cell lung cancer [0.03%]
用于治疗非小细胞肺癌脑转移的 investigational 新药
Pasquale Vitale,Giuseppe Lamberti,Ilaria di Giovanni et al.
Pasquale Vitale et al.
Introduction: Lung cancer is a leading cause of cancer-related mortality. Brain metastasis (BM) has a high incidence in non-small cell lung cancer (NSCLC) and represents a devastating complication associated with poor pro...